Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: A Population-based analysis.
Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D.
Cancer. 2012 Jan 31. doi: 10.1002/cncr.27422. [Epub ahead of print]
Related citations
Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal mutome and microRNAome.
Landi D, Gemignani F, Pardini B, Naccarati A, Garritano S, Vodicka P, Vodickova L, Canzian F, Novotny J, Barale R, Landi S.
Cancer. 2012 Jan 26. doi: 10.1002/cncr.27435. [Epub ahead of print]
A snapshot of smokers after lung and colorectal cancer diagnosis.
Park ER, Japuntich SJ, Rigotti NA, Traeger L, He Y, Wallace RB, Malin JL, Zallen JP, Keating NL.
Cancer. 2012 Jan 23. doi: 10.1002/cncr.26545. [Epub ahead of print]
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
Wolff RA, Fuchs M, Di Bartolomeo M, Hossain AM, Stoffregen C, Nicol S, Heinemann V.
Cancer. 2011 Dec 27. doi: 10.1002/cncr.26692. [Epub ahead of print]
Folate may help lower risk of colorectal cancer.
Printz C.
Cancer. 2011 Dec 1;117(23):5249. doi: 10.1002/cncr.26674. No abstract available.
Colonoscopy screening rates among patients of colonoscopy-trained African American primary care physicians.
Xirasagar S, Hurley TG, Burch JB, Mansaray A, Hébert JR.
Cancer. 2011 Nov 15;117(22):5151-60. doi: 10.1002/cncr.26142. Epub 2011 Apr 26.
Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.
Mack CD, Carpenter W, Meyer AM, Sanoff H, Stürmer T.
Cancer. 2012 Jun 1;118(11):2925-34. doi: 10.1002/cncr.26622. Epub 2011 Nov 9.
Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients.
Won HH, Lee J, Park JO, Park YS, Lim HY, Kang WK, Kim JW, Lee SY, Park SH.
Cancer. 2012 Jun 1;118(11):2828-36. doi: 10.1002/cncr.26614. Epub 2011 Oct 21.
Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N.
Cancer. 2011 Oct 21. doi: 10.1002/cncr.26613. [Epub ahead of print]
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Wettergren Y, Carlsson G, Odin E, Gustavsson B.
Cancer. 2012 Jun 1;118(11):2935-43. doi: 10.1002/cncr.26595. Epub 2011 Oct 21.
Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer.
Takeda Y, Shinzaki S, Okudo K, Moriwaki K, Murata K, Miyoshi E.
Cancer. 2011 Oct 17. doi: 10.1002/cncr.26490. [Epub ahead of print]
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN.
Cancer. 2011 Oct 1;117(19):4484-92. doi: 10.1002/cncr.26036. Epub 2011 Mar 28.
Preferences for colorectal cancer screening tests and screening test use in a large multispecialty primary care practice.
Hawley ST, McQueen A, Bartholomew LK, Greisinger AJ, Coan SP, Myers R, Vernon SW.
Cancer. 2012 May 15;118(10):2726-34. doi: 10.1002/cncr.26551. Epub 2011 Sep 21.
Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome.
Bozzao C, Lastella P, Ponz de Leon M, Pedroni M, Di Gregorio C, D'Ovidio FD, Resta N, Prete F, Guanti G, Stella A.
Cancer. 2011 Sep 15;117(18):4325-35. doi: 10.1002/cncr.26022. Epub 2011 Mar 8.
Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer.
Slattery ML, Lundgreen A, Herrick JS, Wolff RK, Caan BJ.
Cancer. 2011 Sep 15;117(18):4175-83. doi: 10.1002/cncr.26018. Epub 2011 Mar 1.
Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.
Hyslop T, Weinberg DS, Schulz S, Barkun A, Waldman SA.
Cancer. 2012 May 1;118(9):2532-40. doi: 10.1002/cncr.26516. Epub 2011 Sep 1.
A functional single nucleotide polymorphism at the promoter region of cyclin A2 is associated with increased risk of colon, liver, and lung cancers.
Kim DH, Park SE, Kim M, Ji YI, Kang MY, Jung EH, Ko E, Kim Y, Kim S, Shim YM, Park J.
Cancer. 2011 Sep 1;117(17):4080-91. doi: 10.1002/cncr.25930. Epub 2011 Feb 24.
Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
Matsusaka S, Mishima Y, Suenaga M, Terui Y, Kuniyoshi R, Mizunuma N, Hatake K.
Cancer. 2011 Sep 1;117(17):4026-32. doi: 10.1002/cncr.25977. Epub 2011 Feb 24.
Is the N1c category of the new American Joint Committee on cancer staging system applicable to patients with rectal cancer who receive preoperative chemoradiotherapy?
Song JS, Chang HJ, Kim DY, Kim SY, Baek JY, Park JW, Park SC, Choi HS, Oh JH.
Cancer. 2011 Sep 1;117(17):3917-24. doi: 10.1002/cncr.25968. Epub 2011 Feb 24.
Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis.
Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE.
Cancer. 2011 Sep 1;117(17):4060-9. doi: 10.1002/cncr.25997. Epub 2011 Mar 22.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on